Cardinal Health

Cardinal Health’s edge is scale and efficient‑scale economics in U.S. drug distribution. Three national players, massive fixed‑cost networks, DEA/FDA compliance, and decades‑long customer relationships make local entry uneconomic. Red Oak Sourcing with CVS adds a negotiated generics cost advantage.

We view moats by component: cost advantage 70/100 (scale, procurement via Red Oak); efficient scale 65/100 (national network with high fixed costs, thin returns deter entrants); switching costs 55/100 (large contracts can and do move, as OptumRx did, but transitions are complex and risky); intangible assets 50/100 (brand and compliance know‑how matter but are not exclusive); network effects 35/100 (some data and contracting benefits in Specialty/MSOs and Nuclear, but not classic two‑sided network power).

Risks to moat: vertical integration by payers/pharmacies, regulatory changes, sustained generic deflation, and execution missteps in Medical. Mix shift to specialty and services could strengthen qualitative moats over time if platforms scale.

Core distribution is a pass‑through business with razor‑thin margins; pricing power is structurally limited.

Where Cardinal does have better latent pricing is in higher‑margin areas: specialty physician MSOs, access/hub services, logistics, at‑Home DME, and Nuclear/theranostics, all of which showed strong profit growth in Q1 FY2026. Still, consolidated gross margin remains low, and competition from McKesson and Cencora constrains pricing.

We therefore credit modest future margin expansion from mix but not classic unilateral pricing power.

Drug distribution volume growth, aging demographics, and GLP‑1 and specialty uptake support steady unit demand. Revenue and cash generation are resilient, though working capital can swing materially quarter‑to‑quarter.

The OptumRx non‑renewal created a one‑time reset but management filled volume with new and existing customers and raised FY2026 guidance.

Non‑opioid litigation risk seems manageable, but opioid cash payments persist through 2038. Geographic and payer concentration tilt risk higher than ‘tollbooth’ peers like Visa, so we stop short of an ‘excellent’ predictability score.

FY2025 operating cash flow was 2.4 billion and FCF 1.85 billion despite 798 million opioid payments; cash was 3.9 billion at year‑end and rose to 4.6 billion at Q1 FY2026. Long‑term obligations including current portion increased to about 9.0 billion at 9/30/25 after funding several acquisitions; interest expense rose accordingly (80 million in Q1 FY2026).

Net debt is reasonable relative to cash generation and the company guides to 3.0–3.5 billion adjusted FCF in FY2026, but we deduct for the multi‑year opioid cash obligation and Medical segment history of impairments. Liquidity is ample with revolvers and CP programs.

Positives: disciplined share repurchases (750 million baseline per year; 375 million ASR in Q1 FY2026), continued dividend growth, and reinvestment in automation and distribution capacity.

Strategy focuses capital toward higher‑margin Specialty and services: acquisitions of ION, GI Alliance (majority), ADS (1.1 billion) and Solaris Health (~1.9 billion) build a scaled multi‑specialty MSO platform. Cautions: Medical segment impairments in FY2023–FY2024, heavier leverage, and integration/return risks from rapid M&A.

We view the current plan as rational, but will judge success on sustained ROIC and cash returns.

CEO Jason Hollar has executed a credible turnaround playbook built on simplification, cost actions, and mix shift; guidance has been raised multiple times and segment profits broadened. CFO Aaron Alt brings large‑scale operator discipline.

That said, the legacy Medical missteps temper the score, and the specialty roll‑up requires careful integration. We see aligned incentives via buybacks and measured dividend growth, and management has communicated multi‑year EPS CAGR and FCF goals consistent with quality‑investor discipline.